within Pharmacolibrary.Drugs.D_Dermatologicals.D10A_AntiAcnePreparationsForTopicalUse.D10AF52_ErythromycinCombinations;

model ErythromycinCombinations
  extends Pharmacolibrary.Drugs.ATC.D.D10AF52;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>D10AF52</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Erythromycin, combined with other agents, is a macrolide antibiotic used for the treatment of acne vulgaris and various other skin infections. These fixed-dose topical combinations target Propionibacterium acnes and have anti-inflammatory effects. The D10AF52 code identifies its use in dermatological topical preparations. Topical combinations of erythromycin are still in clinical use for acne, though resistance concerns exist.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical administration in healthy adults; no direct pharmacokinetic studies on erythromycin combination D10AF52 found. Estimates extrapolated from known topical erythromycin formulations and related macrolide antibiotics.</p><h4>References</h4><ol><li><p>Fitton, A, &amp; Goa, KL (1991). Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. <i>Drugs</i> 41(5) 780–798. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199141050-00007&quot;>10.2165/00003495-199141050-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1712709/&quot;>https://pubmed.ncbi.nlm.nih.gov/1712709</a></p></li><li><p>Guay, DR (2007). Topical clindamycin in the management of acne vulgaris. <i>Expert opinion on pharmacotherapy</i> 8(15) 2625–2664. DOI:<a href=&quot;https://doi.org/10.1517/14656566.8.15.2625&quot;>10.1517/14656566.8.15.2625</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17931096/&quot;>https://pubmed.ncbi.nlm.nih.gov/17931096</a></p></li><li><p>van Hoogdalem, EJ (1998). Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. <i>Journal of the European Academy of Dermatology and Venereology : JEADV</i> 11 Suppl 1 S13–S29. DOI:<a href=&quot;https://doi.org/10.1111/j.1468-3083.1998.tb00902.x&quot;>10.1111/j.1468-3083.1998.tb00902.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9891904/&quot;>https://pubmed.ncbi.nlm.nih.gov/9891904</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end ErythromycinCombinations;
